Patent · US Active

Antibodies against prostate-specific stem cell antigen and use thereof

US9200078B2 · kind B2 · utility

13Cited by
0References
19Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 29, 2012
Grant dateDec 1, 2015
Priority date—
Expiry dateJan 13, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumor diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.